Receptor Binding and Predictive Toxicology

Amendment No. 2 is to revise response to question 14, to respond to formal questions submitted in response to the solicitation, and to update solicitation provisions, clauses, and attachments as specified in the Amendment.
Please note that the Proposal Due Date: Monday, July 2, 2018, 3:00 PM EST remains unchanged.
Note: (1) The offeror should acknowledge on the cover page or first page of its business and technical proposals receipt of the RFP and this Amendment..

Added: Jun 27, 2018 6:22 pm Amendment No. 2 is to revise response to question 14, to respond to formal questions submitted in response to the solicitation, and to update solicitation provisions, clauses, and attachments as specified in the Amendment.

Please note that the Proposal Due Date: Monday, July 2, 2018, 3:00 PM EST remains unchanged.

Note: (1) The offeror should acknowledge on the cover page or first page of its business and technical proposals receipt of the RFP and this Amendment.

Amendment No. 1 is to respond to formal questions submitted in response to the solicitation and to update solicitation provisions, clauses, and attachments as specified in the Amendment.
Please note that the Proposal Due Date: Monday, July 2, 2018, 3:00 PM EST remains unchanged.
Note: (1) The offeror should acknowledge on the cover page or first page of its business and technical proposals receipt of the RFP and this Amendment.

.

Added: Jun 27, 2018 12:26 pm

Amendment No. 1 is to respond to formal questions submitted in response to the solicitation and to update solicitation provisions, clauses, and attachments as specified in the Amendment.

Please note that the Proposal Due Date: Monday, July 2, 2018, 3:00 PM EST remains unchanged.

Note: (1) The offeror should acknowledge on the cover page or first page of its business and technical proposals receipt of the RFP and this Amendment.

This modification is to upload the RFP No. NIHDA201800068. Proposals are due by July 2, 2018 by 3:00pm and must be submitted via the electronic Contract Proposal Submission (eCPS) website at https://ecps.nih.gov. Please note that creating an eCPS account to submit a proposal may take up to three (3) business days. Please refer to Attachment 1 for proposal submission instructions..

Added: Jun 01, 2018 1:09 pm This modification is to upload the RFP No. NIHDA201800068. Proposals are due by July 2, 2018 by 3:00pm and must be submitted via the electronic Contract Proposal Submission (eCPS) website at https://ecps.nih.gov. Please note that creating an eCPS account to submit a proposal may take up to three (3) business days. Please refer to Attachment 1 for proposal submission instructions. 

The National Institute on Drug Abuse (NIDA) plans to solicit proposals under full and open competition procedures from qualified organizations having the capability to perform in vitro receptor binding assays on a wide variety of receptor targets, and perform follow-up binding and functional assays using appropriate in vitro biological systems. In addition, an interested organization should have the capacity to perform in vitro predictive toxicology assays. Specifically, the project requires the following tasks to be performed:
Task 1: Receptor Profile Screening (screening a compound at approximately 64 sites) Task 2: Receptor Binding Affinity and/or Functional Activity, (Computing IC50/Ki at sites showing activity in the profile screening or other sites of interest to NIDA); Task 3: Predictive Toxicology and Pharmacokinetic Testing (Cyp450, hERG channel, genotoxicity (Ames test). Task 4: Assay Development (interested organizations may be asked from time to time to submit a proposal to develop an assay not in their current catalog).
This is a follow-on procurement to Contract Number HHSN271201300025C titled "Receptor Profiling and Predictive Toxicology." NIDA anticipates the award of a single indefinite delivery, indefinitely quantity (IDIQ) task order contract for a period of performance of five years. NIDA may award either cost reimbursement and/or fixed price task orders under this contract. NIDA anticipates that at least one task order will be awarded with the contract.
Many of the compounds that will be tested will come from private sources (e.g., the pharmaceutical industry) that wish to keep information and data confidential (e.g. until patents are filed). In most cases, NIDA will have signed a confidentiality agreement with the provider indicating that the data obtained will not be released without the provider's written permission. For this reason, the Contractor may not publish, present, or otherwise disclose the results of studies on test compounds unless the NIDA Contracting Officer grants written permission to publish or otherwise disclose this information.
MANDATORY CRITERIA
Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970 at the time of submission of the proposal. In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule 1 controlled substances prior to awarding the contract.
NOTICE
RFP No. NIHDA201800068 will be available electronically on or about 15 days from the date of this posting. You can access the RFP through the FedBizOpps (URL: http://fedbizopps.gov) or through the NIDA website (URL: http://www.drugabuse.gov/funding/funding-opportunities/nida-requests-contract-proposals-rfps). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due 30 days from the release date. NIDA anticipates an award on or before August 15, 2018. NIDA will consider proposals submitted by any responsible offeror.
Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons or organizations may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.
This advertisement does not commit the Government to award a contract..

Added: Apr 09, 2018 12:03 pm The National Institute on Drug Abuse (NIDA) plans to solicit proposals under full and open competition procedures from qualified organizations having the capability to perform in vitro receptor binding assays on a wide variety of receptor targets, and perform follow-up binding and functional assays using appropriate in vitro biological systems. In addition, an interested organization should have the capacity to perform in vitro predictive toxicology assays. Specifically, the project requires the following tasks to be performed:

Task 1: Receptor Profile Screening (screening a compound at approximately 64 sites) Task 2: Receptor Binding Affinity and/or Functional Activity, (Computing IC50/Ki at sites showing activity in the profile screening or other sites of interest to NIDA); Task 3: Predictive Toxicology and Pharmacokinetic Testing (Cyp450, hERG channel, genotoxicity (Ames test). Task 4: Assay Development (interested organizations may be asked from time to time to submit a proposal to develop an assay not in their current catalog).

This is a follow-on procurement to Contract Number HHSN271201300025C titled "Receptor Profiling and Predictive Toxicology." NIDA anticipates the award of a single indefinite delivery, indefinitely quantity (IDIQ) task order contract for a period of performance of five years. NIDA may award either cost reimbursement and/or fixed price task orders under this contract. NIDA anticipates that at least one task order will be awarded with the contract.

Many of the compounds that will be tested will come from private sources (e.g., the pharmaceutical industry) that wish to keep information and data confidential (e.g. until patents are filed). In most cases, NIDA will have signed a confidentiality agreement with the provider indicating that the data obtained will not be released without the provider's written permission. For this reason, the Contractor may not publish, present, or otherwise disclose the results of studies on test compounds unless the NIDA Contracting Officer grants written permission to publish or otherwise disclose this information.

MANDATORY CRITERIA
Due to the nature of the compounds which will be evaluated under this contract, it is mandatory that offerors possess a DEA Research Registration for Schedules II to V in order to handle substances under the Controlled Substances Act of 1970 at the time of submission of the proposal. In addition, the successful offeror must either possess, or demonstrate the ability to obtain a DEA registration for Schedule 1 controlled substances prior to awarding the contract.

NOTICE
RFP No. NIHDA201800068 will be available electronically on or about 15 days from the date of this posting. You can access the RFP through the FedBizOpps (URL: http://fedbizopps.gov) or through the NIDA website (URL: http://www.drugabuse.gov/funding/funding-opportunities/nida-requests-contract-proposals-rfps). All information required for the submission of a proposal will be contained in or accessible through the RFP package. Responses to the RFP will be due 30 days from the release date. NIDA anticipates an award on or before August 15, 2018. NIDA will consider proposals submitted by any responsible offeror.

Based upon market research, the Government is not using the policies contained in Part 12, Acquisition of Commercial Items, in its solicitation for the described supplies or services. However, interested persons or organizations may identify to the Contracting Officer their interest and capability to satisfy the Government's requirement with a commercial item within 15 days of this notice.

This advertisement does not commit the Government to award a contract.